On March 31, 2026, William Blair upgraded 10x Genomics from “Market Perform” to “Outperform,” highlighting its best-in-class genomics platforms and exposure to growing demand for large-scale ...
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in ...
William Blair upgraded 10x Genomics Inc. TXG stock, citing it as the best-in-class technology and is well-positioned to ...
“By uniting CareDx’s clinical and diagnostic expertise with 10x Genomics’ transcriptomics technologies, we’re building upon a robust scientific foundation to drive future organ-health innovation ...
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling CareDx will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results